Integra LifeSciences Holdings Co. (NASDAQ:IART) Expected to Post Third Quarter 2022 Earnings of $0.79 Per Share

0

Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) – Equity researchers at Zacks Research have cut their third-quarter 2022 earnings estimates for Integra LifeSciences shares in a research report delivered to clients and investors on Monday, September 19. Zacks Research analyst U. Biswas now expects the life sciences company to earn $0.79 per share for the quarter, down from its previous forecast of $0.80. The consensus estimate for Integra LifeSciences’ current annual earnings is $3.15 per share. Zacks Research also released estimates for Integra LifeSciences fourth quarter 2022 earnings at $0.88 EPS, full year 2022 earnings at $3.24 EPS, Q1 2023 earnings at $0.79 EPS , 2023 Q2 earnings at $0.90 EPS, 2023 Q3 earnings at $0.95 EPS, 2023 fiscal year earnings at $3.57 EPS, 2024 Q1 earnings at $0.70 EPS and FY2024 earnings at $3.71 EPS.

Several other research companies have also recently commented on the IART. Truist Financial cut its price target on Integra LifeSciences shares from $70.00 to $56.00 and set a “hold” rating for the company in a Wednesday, July 20 research note. Piper Sandler reduced her target price on Integra LifeSciences shares from $55.00 to $50.00 in a Wednesday, August 24 research note. Morgan Stanley lowered its price target on Integra LifeSciences shares from $59.00 to $58.00 and set an “equal weight” rating for the company in a Thursday, August 25 research note. Finally, TheStreet upgraded Integra LifeSciences’ shares from a “b-” to a “c+” rating in a Friday, July 8 research note. One analyst rated the stock with a sell rating, four issued a hold rating and three assigned the company a buy rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $65.43.

Integra LifeSciences Price Performance

NASDAQ:IART opened at $44.59 on Wednesday. The stock has a market capitalization of $3.72 billion, a P/E ratio of 22.63, a PEG ratio of 1.51 and a beta of 1.12. Integra LifeSciences has a one-year minimum of $44.21 and a one-year maximum of $74.98. The company has a fifty-day moving average price of $52.11 and a 200-day moving average price of $57.61. The company has a debt ratio of 0.90, a current ratio of 3.85 and a quick ratio of 2.76.

Institutional investors weigh in on Integra LifeSciences

A number of hedge funds have recently changed their positions in the IART. Crossmark Global Holdings Inc. increased its stake in Integra LifeSciences by 2.6% in Q1. Crossmark Global Holdings Inc. now owns 7,502 shares of the life sciences company worth $482,000 after acquiring 190 additional shares in the last quarter. The Texas Permanent School Fund increased its holdings in Integra LifeSciences by 0.4% during the second quarter. Texas Permanent School Fund now owns 51,833 shares of the life sciences company worth $2,801,000 after acquiring 191 additional shares in the last quarter. NorthCrest Asset Management LLC increased its stake in Integra LifeSciences by 1.5% during the 1st quarter. NorthCrest Asset Management LLC now owns 13,800 shares of the life sciences company worth $887,000 after acquiring 200 additional shares in the last quarter. Campbell Newman Asset Management Inc. increased its stake in Integra LifeSciences by 1.9% during the first quarter. Campbell Newman Asset Management Inc. now owns 12,743 shares of the life sciences company worth $819,000 after acquiring 243 additional shares in the last quarter. Finally, Inspire Investing LLC increased its stake in Integra LifeSciences by 6.9% during the 2nd quarter. Inspire Investing LLC now owns 3,890 shares of the life sciences company worth $210,000 after acquiring 252 additional shares in the last quarter. Institutional investors and hedge funds hold 87.33% of the company’s shares.

Insider activity

In related news, manager Raymond G. Murphy sold 8,000 shares in a trade dated Friday, August 5. The shares were sold at an average price of $55.78, for a total transaction of $446,240.00. Following the completion of the sale, the administrator now owns 40,825 shares of the company, valued at approximately $2,277,218.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. In related news, manager Raymond G. Murphy sold 8,000 shares in a trade dated Friday, August 5. The shares were sold at an average price of $55.78, for a total transaction of $446,240.00. Following the completion of the sale, the administrator now owns 40,825 shares of the company, valued at approximately $2,277,218.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Additionally, Executive Vice President Lisa Evoli sold 1,165 shares in a trade dated Wednesday, August 10. The stock was sold at an average price of $55.81, for a total transaction of $65,018.65. Following the sale, the executive vice president now owns 17,997 shares of the company, valued at approximately $1,004,412.57. The disclosure of this sale can be found here. In the past 90 days, insiders have sold 9,602 shares of the company worth $536,067. 4.20% of the shares are currently held by company insiders.

About Integra LifeSciences

(Get a rating)

Integra LifeSciences Holdings Corporation develops, manufactures and markets surgical implants and medical devices for use in neurosurgery, extremity reconstruction and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The Company offers neurosurgery and neuro-critical care products, including tissue ablation equipment, dural repair products, cerebrospinal fluid management devices, intracranial monitoring equipment and cranial stabilization equipment; and headlamps and surgical instruments, as well as asset management software and support, and aftermarket services.

Featured articles

Earnings history and estimates for Integra LifeSciences (NASDAQ: IART)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Integra LifeSciences, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market goes wild…and Integra LifeSciences didn’t make the list.

Although Integra LifeSciences currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Share.

Comments are closed.